Who
Matthew W. Foehr
President and CEO
Company insider
Files Form 4 as: President and CEO, OmniAb; Director, Viking Therapeutics; President and COO, Ligand Pharmaceuticals; CLO & Secretary, OmniAb Operations; Director, FF EAI Robotics Ecosystem; Sr. VP Technical Operations, Connetics.
In numbers
- Trades disclosed
- 383
- Buys
- 27
- Sells
- 34
- Bought
- $8.5M
- Sold
- $33.7M
- Companies
- 6
- Companies where not an officer
- 2
- First trade
- 1 Feb 2006
- Last trade
- 7 Apr 2026
- Last filed
- 7 Apr 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Apr 2026filed 7 Apr 2026 | OABI OmniAbLife-science tools | SEC FORM 4 Code M | —36,459 at $0.00 | filing |
| 7 Apr 2026filed 7 Apr 2026 | OABI OmniAbLife-science tools | SEC FORM 4 Sold | $29K19,244 at $1.49 | filing |
| 7 Apr 2026filed 7 Apr 2026 | OABI OmniAboption or derivative · Life-science tools | SEC FORM 4 Code M | —36,459 at $0.00 | filing |
| 7 Apr 2026filed 7 Apr 2026 | OABI OmniAboption or derivative · Life-science tools | SEC FORM 4 Code M | —36,459 at $0.00 | filing |
| 7 Apr 2026filed 7 Apr 2026 | OABI OmniAbLife-science tools | SEC FORM 4 Code M | —36,459 at $0.00 | filing |
| 7 Apr 2026filed 7 Apr 2026 | OABI OmniAbLife-science tools | SEC FORM 4 Sold | $29K19,244 at $1.49 | filing |
| 18 Feb 2026filed 18 Feb 2026 | OABI OmniAbLife-science tools | SEC FORM 4 Code M | —58,333 | filing |
| 18 Feb 2026filed 18 Feb 2026 | OABI OmniAbLife-science tools | SEC FORM 4 Sold | $53K30,843 at $1.71 | filing |
| 18 Feb 2026filed 18 Feb 2026 | OABI OmniAboption or derivative · Life-science tools | SEC FORM 4 Code M | —58,333 at $0.00 | filing |
| 18 Feb 2026filed 18 Feb 2026 | OABI OmniAboption or derivative · Life-science tools | SEC FORM 4 Code M | —58,333 at $0.00 | filing |
| 18 Feb 2026filed 18 Feb 2026 | OABI OmniAboption or derivative · Life-science tools | SEC FORM 4 Code A | —156,250 at $0.00 | filing |
| 18 Feb 2026filed 18 Feb 2026 | OABI OmniAboption or derivative · Life-science tools | SEC FORM 4 Code A | —1,562,500 at $0.00 | filing |
| 18 Feb 2026filed 18 Feb 2026 | OABI OmniAboption or derivative · Life-science tools | SEC FORM 4 Code A | —156,250 at $0.00 | filing |
| 18 Feb 2026filed 18 Feb 2026 | OABI OmniAboption or derivative · Life-science tools | SEC FORM 4 Code A | —1,562,500 at $0.00 | filing |
| 18 Feb 2026filed 18 Feb 2026 | OABI OmniAbLife-science tools | SEC FORM 4 Code M | —58,333 | filing |
| 18 Feb 2026filed 18 Feb 2026 | OABI OmniAbLife-science tools | SEC FORM 4 Sold | $53K30,843 at $1.71 | filing |
| 17 Feb 2026filed 17 Feb 2026 | OABI OmniAbLife-science tools | SEC FORM 4 Sold | $35K20,754 at $1.70 | filing |
| 17 Feb 2026filed 17 Feb 2026 | OABI OmniAbLife-science tools | SEC FORM 4 Sold | $35K20,754 at $1.70 | filing |
| 16 Feb 2026filed 17 Feb 2026 | OABI OmniAbLife-science tools | SEC FORM 4 Code M | —36,458 at $0.00 | filing |
| 16 Feb 2026filed 17 Feb 2026 | OABI OmniAboption or derivative · Life-science tools | SEC FORM 4 Code M | —36,458 at $0.00 | filing |
News
Prediction: $1,000 Invested in Viking Therapeutics Today Will Be Worth This Much in 5 YearsVKTX · fool.com · 20 Oct 2026Viking Therapeutics Initiates Pivotal Phase 3 Trial: Here's Why Investors Have Reason for Optimism After a Disappointing Phase 2VKTX · fool.com · 20 Oct 2026Viking Therapeutics Just Raised $575 Million. Here's What It Means for the Obesity Stock's Next Chapter.VKTX · fool.com · 18 Oct 2026
0 headlines in the last 90 days name Matthew W. Foehr; 3 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.